

## Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices

November 4, 2016

### Participant List

**Shashi Amur**

Scientific Lead, Biomarker Qualification Program, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Jiri Aubrecht**

Senior Director, Global Lead for Clinical and Translational Safety Biomarkers, Drug Safety R&D, Pfizer

**Amanda Baker**

Research Scientist, Predictive Safety Testing Consortium, Critical Path Institute and Associate Professor of Medicine, University of Arizona

**Robert Becker**

Chief Medical Officer, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, U.S. Food and Drug Administration

**Martha A. Brumfield**

President and Chief Executive Officer, Critical Path Institute

**ShaAvhrée Buckman-Garner**

Director, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Jennifer Burkey**

Scientific Director, Predictive Safety Testing Consortium, Critical Path Institute

**Gregory Daniel**

Clinical Professor, Duke Fuqua School of Business and Deputy Director, Duke-Margolis Center for Health Policy, Duke University

**Martha Donoghue**

Acting Associate Director, Division of Oncology Products 2, Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Meredith Freed**

Senior Research Assistant, Duke-Margolis Center for Health Policy, Duke University

**Steven Gutman**

Strategic Advisor, Illumina, Inc.

**Patrick Harrington**

Senior Clinical Virology Reviewer, Division of Antiviral Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Kylie Haskins**

Biologist, Biomarker Qualification Program, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**John A. Kadavil**

Lead Pharmacologist, Office of Study Integrity and Surveillance, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Gary J. Kelloff**

Special Advisor, Cancer Treatment and Diagnosis, National Cancer Institute

**Nicholas King**

Senior Project Manager, Predictive Safety Testing Consortium, Critical Path Institute

**Gabriela Lavezzari**

Research Director, Duke-Margolis Center for Health Policy, Duke University

**Jean Lee**

Consultant, BioQaulQuan

**Christopher Leptak**

Director, Office of New Drugs Regulatory Science Program and Co-Director, Biomarker Qualification Program, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Susan McCune**

Deputy Director, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Vasum Peiris**

Chief Pediatric Medical Officer - Pediatrics and Special Populations, Office of the Center Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration

**Steven Piccoli**

Research Fellow, Bristol-Myers Squibb

**Elizabeth Richardson**

Managing Associate, Duke-Margolis Center for Health Policy, Duke University

**Afshin Safavi**

Chief Scientific Officer, BioAgilytix Labs

**John-Michael Sauer**

Executive Director, Predictive Safety Testing Consortium, Critical Path Institute

**Shelli Schomaker**

Principal Scientist, Pfizer

**Meena Subramanyam**

Vice President - Biomarker Strategy, Global Biomarker Discovery and Development, Biogen

**Sue-Jane Wang**

Associate Director and Biostatistics Lead/Coordinator and Biostatistics Office Liaison to OTS for the CDER Biomarker Qualification Program, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration